Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press

Executive Summary

Analysis published in the Journal of the American Medical Association is the latest to argue that PCSK9 inhibitors are not cost-effective.


Related Content

New CV Outcomes Study May Mean Big Boost For Amgen's Repatha Market
Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math
Will Physician Demand For Repatha Put Pressure On Payer Restrictions?
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds
Amgen Plugs Away On Repatha, With Hope For New Monthly Product
PCSK9 Sponsors, Payers In The Ring At ACC
Amgen’s Statin Intolerance Study May Not Cure What Ails PCSK9 Inhibitors
PCSK9 List Price Discounts Of 67% To 85% Suggested By ICER Analysis
Formulary Focus: PCSK9 Drug Prices May Lead Payers To Impose Coverage Restrictions


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts